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Abstract 
Duchenne muscular dystrophy (DMD) is X-linked recessive neuromuscular disorders caused due to mutation in 
dystrophin gene, leading to progressive muscle weakness. This study was done to identify mutation in 
dystrophin gene in Nepalese patients with DMD using Multiplex Ligation Dependent Probe Amplification 
(MLPA) assay in Nepal. Twenty one patients from different regions of Nepal, who were clinically diagnosed as 
DMD were enrolled in the study. Peripheral blood samples were collected in EDTA vials, gDNA was extracted, 
and deletion mutation in the dystrophin gene was analysed using Multiplex Ligation Dependent Probe 
Amplification (MLPA) assay. 
Exon deletion mutation in the dystrophin gene was observed in 14 (66.6%) out of 21 DMD cases. The most 
common exon deletion was observed and confined in exon 7-14 and 45-53 of dystrophin gene. The location of 
deletion in dystrophin gene is apparently non-random with a preponderance found in the hot spot regions. Use of 
MLPA is useful in detecting copy number changes in DMD proband and suspected carriers in Nepal. 
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Introduction 
Duchenne and Becker muscular dystrophies (DMD & 
BMD) are X-linked recessive neuromuscular 
disorders with incidence of 1 in 3,500 and 1 in 30,000 
live male births, respectively [1]. DMD is 
characterized by progressive muscle weakness with 
onset at 3-5 years of age, leading to loss of 
ambulation by 10-12 years of age without treatment. 
Respiratory, orthopaedic, and cardiac complications 
emerge with age, and without intervention, the mean 
age at death is around 19 years [2]. 
Both DMD and BMD are caused by mutations in the 
dystrophin gene (MIM 300377), one of the largest 
known human genes, spanning about 2.4 Mb of 
genomic DNA [3]. The most common mutations in 
the DMD gene are the deletion or duplication of one 
or more exons [3]. Mutations lead to an absence of or 
defect in the dystrophin protein, which results in 
progressive muscle degeneration leading to loss of 
independent ambulation by the age of 13 years. 
Variable phenotypic expression relates mainly to the 
type of mutation and its effect on the production of 
dystrophin [4]. 
Muscular dystrophy is diagnosed on the basis of 
clinical examination, raised creatine phosphokinase 
(CPK) level, muscle biopsy and dystrophin gene 
mutation analysis. The genetic tests commonly used 
to identify dystrophin mutations are multiplex 
polymerase chain reaction (mPCR), multiplex 
ligation dependent probe amplification (MLPA), 
single condition amplification/internal primer, and 
multiplex amplifiable probe hybridization [5]. 
Mutation analysis of dystrophin gene in DMD/BMD 
has been performed in several countries [2, 3]. 
However, no such studies have been performed in 
Nepal. MLPA, a simple and cheaper genetic test to 
detect duplication/ deletion mutation, could be a 
better tool for genetic diagnosis of DMD in Nepalese 
patients; thereby assisting in timely diagnosis, 
treatment and management. We conducted present 
study among clinically diagnosed DMD patients to 
find the mutation pattern in dystrophin gene using 
MLPA and test the efficacy of MLPA in identifying 
mutation in DMD patients in the Nepalese context. 
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Materials and Methods  
The study was conducted among 21 clinically 
diagnosed DMD patients from different regions of 
Nepal, who were referred to Muscular Dystrophy 
Foundation-Nepal (MDF-Nepal). Diagnosis of DMD 
was done on the basis of clinical presentations and 
markedly elevated serum creatine phosphokinase 
(CPK) levels. Proper genetic counselling was done, 
and consent was taken from each patient and their 
parents. 
Peripheral blood samples (5 ml) were collected from 
each patient in EDTA vials and transported to 
laboratory of Central Department of Biotechnology, 
Tribhuvan University, Kirtipur maintaining cold 
chain. The samples were stored at -200 C until 
analysis. Genomic DNA was isolated from blood, as 
recommended by the MRC-Holland, by using the 
extraction method of the QIAamp DNA mini kit [6]. 
The absorbance of DNA samples were measured at 
230 nm, 260 nm and 280 nm using the UV 
spectrophotometer to check for purity of DNA 
samples required for MLPA assay. 
A commercial MLPA kit (MRC Holland) with probes 
of P034 (DMD exons 1-10, 21-30, 41-50, and 61-70) 
and P035 (DMD exons 11-20, 31-40, 51-60, and 71-79) 
was used to detect DMD deletion/duplication in 
DMD patients according to the manufacturer’s 
recommended protocol (Amsterdam, Netherlands). 
50-250 ng of genomic DNA, in a volume of 5 µL Tris-
EDTA, was denatured at 980 C for 5 min, cooled 
down, and then mixed with MLPA P034 or P035 
probemix. The mixture was then heated to 950 C for 5 
min and incubated at 600 C overnight for probe 
hybridization. After 16 hours, ligation was 
performed with Ligase-65 enzyme at 540 C for 15 min 
and Ligase-65 enzyme was inactivated at 980 C for 5 
min. Then, PCR amplification was performed with 
specific SALSA FAM PCR primers (5’-
GGGTTCCCTAAGGGTTGGA-3’). After that, the 
mixture was separated by capillary electrophoresis 
and then analyzed using ABI-310 Genetic Analyzer 
[7]. 
The Genescan analysis software in the ABI-310 
Genetic Analyzer analyzed the raw data to quantify 
the DNA fragments and determine the size of the 
fragments by comparing them to fragments in a size 
standard. The electropherograms of test samples 
were analyzed by comparing with the peak pattern 
of the male and female reference samples. The novel 
software Coffalyser.net was used to analyze the data 
obtained after the capillary electrophoresis run which 
was further confirmed by visual assessment by 
overlaying two fragment profiles and comparing the 
relative intensities of fragments. The relative peak 
ratio (RPR) of every single exon was plotted to its 
corresponding bar chart [8]. Absence of peaks 
corresponding to two or more contiguous exons was 
taken to represent a genuine deletion. The absence of 
only one peak in males, corresponding to a single 
exon, were also recorded which are yet to be 
investigated further by applying the novel methods 
as PCR primer flanking the exons in question or by 
sequencing. The framedness of the mutation in 
probands were also estimated by using the 
dystrophin exonic deletions/duplications reading 
frame checker 1.9 as recommended by MRC Holland. 
The data from the study was entered into ms excel 
and analyzed using SPSS version 11.0. 
Results  
The mean age of DMD patients at the time of study 
was 11.4 years (age range from 8-18 years). All the 
patients had very high serum CPK level (median: 
6245 U/L, range:  2100-32890 U/L). The genomic 
DNA extracted from samples had concentration 
range within 27-59 μg/mL. The ratio of the optical 
density (OD) of DNA samples at 260 nm and 280 nm 
ranged from 1.5-2.0 with mean OD 1.76. Among the 
21 samples of DMD analyzed by MLPA assay, 
deletions were observed at various exons of 
dystrophin gene in 14 samples. Seven samples 
however did not have any deletion or duplication in 
the exons. Thus, MLPA tool could detect mutations 
in about 66.6% (14 of 21 samples). The most prevalent 
exonic deletion regions were found to be confined in 
the exon 7-14 and 45-53. Deletion mutations at 
different exons observed in samples are shown in 
table 1. Similarly, electropherograms of control 
sample and test sample after MLPA assay with 
SALSA probe mix P034 and P035 are shown in figure 
1. 
As indicated by the dystrophin exonic deletions/ 
duplications reading frame checker 1.9, all the 14 
samples with detection of deletion mutation were 
detected by MLPA assay have out of frame 
mutations suggesting that the samples were those of 
DMD patients. But the confirmation of the 
framedness is yet to be made by gene sequencing, 
and the 7 samples with negative MLPA result need 
further genetic testing like sequencing. 
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Table 1: Exon deletions detected by MLPA assay in 
DMD patients 
Case  Age 
(years) 
Serum 
Creatine 
kinase level 
(U/L) 
Exon 
deletions 
Phenotype  
1 5 12122 48-50 DMD 
2 7 3412 52 DMD 
3 6 14467 10-43 DMD 
4 8 1287 52 DMD 
5 9 11580 45 DMD 
6 5 24200 51-53 DMD 
7 14 22000 45-50 DMD 
8 5 21887 46-49 DMD 
9 12 2700 52 DMD 
10 11 2100 51 DMD 
11 8 4328 12-14 DMD 
12 9 3220 51 DMD 
13 6 9123 45 DMD 
14 7 6245 7-9 DMD 
 
Discussion 
In Nepal, DMD/BMD patients are generally 
diagnosed late due to the lack of complete 
understanding of the disease, poor screening of 
paediatric group for muscular dystrophy and lack of 
genetic diagnostic facilities in the country. Most of 
the cases are diagnosed on the basis of history given 
by the parents, positive clinical signs of DMD and 
very high CK level in the blood. For the diagnosis at 
the gene level clients usually go to or the sample is 
send outside Nepal, which is not accessible and 
affordable to many of the parents. This study to 
detect deletion mutation in DMD using MLPA is first 
genetic pilot study in Nepal.  
Among the 21 samples of clinically diagnosed DMD 
patients, deletion of dystrophin exon was found in 14 
samples (66.6%). However, 7 samples (33.3%) did not 
show any deletion or duplication. Thus, MLPA was 
efficient in accurately confirming mutations in about 
67% of all the cases. A number of studies have found 
MLPA assay to be highly sensitive diagnostic assay 
to identify mutation in DMD and BMD patients [9]. 
In the study to evaluate the efficacy of MLPA 
technique in comparison with the traditional 
multiplex PCR assay in detection of exon deletions 
and duplications of the DMD gene by Lai et al., 
MLPA was able to detect all the known deletions and 
duplications; it detected four additional mutations 
that had been missed by multiplex PCR  [10]. In a 
study in China amongst 70 DMD/BMD patients, 
MLPA detected exonic deletions in 42 patients (60%), 
exonic duplications in 7 patients (10%) and 21 
patients (30%) showed normal results [11]. 
In the present study, only exons deletion was 
observed. No exon duplication was found. We found 
most prevalent exonic deletion regions to be confined 
in the exons 7-14 and 45-53. One, 3, 4, 6 and 44 exons 
deletion was observed in 7, 4, 1, 1 and 1 patients 
respectively. No novel mutations were identified in 
this study. In a study in Iranian DMD/BMD patients, 
30.9 % of patients had single exon deletion, while 
group and contiguous exon deletions were identified 
in 41% of the patients [12]. The most numerous exon 
deletions included exons 45-50, and two exons 3-5 
and 41-43 duplications (1.4 %) was observed in a 
BMD and a DMD patient, respectively [12]. In a 
study in Polish DMD/BMD patients, Zimowski et al. 
identified 110 deletions, 22 duplication (in one 
patient two different duplications were detected) and 
2 point mutations. Deletions involved mainly exons 
45-54 and 3-21, whereas most duplication involved 
exons 3-18 [13]. It has been found that deletions 
account for approximately 60-65% of mutations and 
duplications for 5-10% in DMD/BMD. The 
remaining cases are mainly point mutations (30-35% 
of the cases). Although deletions encompass all 79 
exons, two deletion hotspots (exons 45-55 and exons 
2-19) are recognized [14]. 
Identification of exon deletion is important to design 
gene therapy by exon skipping method that is an 
emerging therapy for DMD that can transform DMD 
into BMD is based on the recovery of reading frame 
induced by alternative splicing of antisense 
oligonucleotides [15]. More patients may benefit 
from individual exon skipping therapies following a 
comprehensive understanding of the correlation 
between genotypes and phenotypes under the 
guidance of large-scale genetic epidemiological 
studies [16]. Similarly identifying disease at earlier 
stage could help in better management of patients 
and thus better life quality. 
This was the first genetic study on DMD in Nepal. 
The location of deletion in dystrophin gene is 
apparently non-random with a preponderance found 
in the hot spot regions in Nepalese population as 
well. Use of MLPA is useful in detecting copy 
number changes in DMD proband and suspected 
carriers. 
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Figure 1. Electropherogram of control sample and test sample after MLPA. Fig. 1A and Fig. 1B are for normal control 
sample with P034 and P035 respectively. Fig. 1C and Fig. 1D are for DMD patient with deletion in dystrophin gene with 
P034 and P035 respectively. 
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